论文部分内容阅读
目的 :观察酪氨酸激酶抑制剂STI5 71在BCR/ABL融合基因阳性表达白血病的治疗效果和副作用。方法 :已确诊BCR/ABL+ 的 8例慢性粒细胞性白血病 (CML)和 1例急性淋巴细胞白血病 (ALL)患者采用STI5 71+Ara -C治疗。结果 :2例CML -慢性期患者均CR至今 ,6例CML -急粒变患者有 2例CR ,其中 1例CR至今已 3 7周 ,1例ALL在第三次血液学CR后经治疗维持CR2 8周后复发。结论 :STI5 71可诱导BCR/ABL+ 白血病患者完全缓解 ,降低骨髓BCR/ABL+ 白血病细胞 ,延长CR期 ,药物副作用轻微易耐受 ,药物作用的个体差异性较大
Objective: To observe the therapeutic effect and side effects of tyrosine kinase inhibitor STI5 71 in BCR / ABL fusion gene positive leukemia. METHODS: Eight patients with chronic myeloid leukemia (CML) and one patient with acute lymphoblastic leukemia (ALL) who had been diagnosed with BCR / ABL + were treated with STI5 71 + Ara-C. Results: CR was present in 2 patients with CML - chronic phase and 2 patients with CR in 6 patients with CML - acute myelograde, of which 1 CR has been 37 weeks and 1 ALL has been treated after the third hematologic CR CR2 relapse after 8 weeks. Conclusion: STI571 can induce complete remission in patients with BCR / ABL + leukemia, reduce bone marrow BCR / ABL + leukemia cells, prolong the CR period, drug side effects are slightly easy to tolerate, the individual differences in drug effect larger